Crystal structure of the putative peptide-binding protein AppA from Clostridium difficile

Peptides play an important signalling role in Bacillus subtilis, where their uptake by one of two ABC-type oligopeptide transporters, Opp and App, is required for efficient sporulation. Homologues of these transporters in Clostridium difficile have been characterized, but their role, and hence that of peptides, in regulating sporulation in this organism is less clear. Here, the oligopeptide-binding receptor proteins for these transporters, CdAppA and CdOppA, have been purified and partially characterized, and the crystal structure of CdAppA has been determined in an open unliganded form. Peptide binding to either protein could not be observed in Thermofluor assays with a set of ten peptides of varying lengths and compositions. Re-examination of the protein sequences together with structure comparisons prompts the proposal that CdAppA is not a versatile peptide-binding protein but instead may bind a restricted set of peptides. Meanwhile, CdOppA is likely to be the receptor protein for a nickel-uptake system.
Source: Acta Crystallographica Section F - Category: Biochemistry Authors: Tags: Clostridium difficile peptide transport OppA AppA sporulation research communications Source Type: research

Related Links:

Abstract In Japan, there is no national surveillance study of Clostridioides (Clostridium) difficile infection (CDI), and details about the epidemiology and treatment status of CDI are unknown. Additionally, clinical practice guidelines (CPGs) for CDI are published by four different institutions. All CPGs recommend that the antimicrobials, vancomycin (VCM) and metronidazole (MNZ), should be selected according to disease severity. However, the trends for VCM and MNZ use in Japan remain unclear. Therefore, this study was aimed at clarifying the secular trends for VCM and MNZ use based on sales data from 2006 to 2015...
Source: Biological and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Biol Pharm Bull Source Type: research
THURSDAY, April 2, 2020 -- From 2011 to 2017, there was a decrease in the estimated national burden of Clostridium difficile infection, according to a study published in the April 2 issue of the New England Journal of Medicine. Alice Y. Guh, M.D.,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
ACS Chemical BiologyDOI: 10.1021/acschembio.0c00066
Source: ACS Chemical Biology - Category: Chemistry Authors: Source Type: research
Clostridioides difficile infection (CDI) is the leading cause of health care –associated infections in the United States. The increasing incidence and recurrence rates of CDI together with its associated morbidity and mortality are great concerns. Newer treatment methods, such as narrow-spectrum antibiotics, monoclonal antibodies, and microbial replacement therapies, are b eing developed and implemented. We searched PubMed to identify published literature from 2010 to 2018 using the following keywords: Clostridium difficile, treatment, and therapy.
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Tags: Review Source Type: research
Publication date: 25 May 2020Source: Journal of Industrial and Engineering Chemistry, Volume 85Author(s): Seong-Min Kim, Han-Gyu Park, Won-Suk Song, Sung-Hyun Jo, Yung-Hun Yang, Yun-Gon Kim
Source: Journal of Industrial and Engineering Chemistry - Category: Chemistry Source Type: research
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 30, 2020-- Seres Therapeutics, Inc., (Nasdaq: MCRB) announced today that the Company has completed enrollment of its SER-109 Phase 3 clinical study, ECOSPOR III. SER-109 is an oral, first-in-field...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
Abstract Clostridioides difficile is an important nosocomial pathogen that produces toxins to cause life-threatening diarrhea and colitis. Toxins bind to epithelial receptors and promote the collapse of the actin cytoskeleton. C. difficile toxin activity is commonly studied in cancer-derived and immortalized cell lines. However, the biological relevance of these models are limited. Moreover, no model is available for examining C. difficile-induced enteritis, an understudied health problem. We hypothesized human intestinal enteroids (HIEs) express toxin receptors and provide a new model to dissect C. difficile cyto...
Source: American Journal of Physiology. Gastrointestinal and Liver Physiology - Category: Physiology Authors: Tags: Am J Physiol Gastrointest Liver Physiol Source Type: research
We report a rare and fatal case of bacteremia due to C. difficile from a Greek hospital. PMID: 32234350 [PubMed - as supplied by publisher]
Source: Anaerobe - Category: Microbiology Authors: Tags: Anaerobe Source Type: research
Conclusion. Our results suggest that baicalin could potentially be used to control C. difficile, and warrant future studies in vivo. PMID: 32216868 [PubMed - as supplied by publisher]
Source: Journal of Medical Microbiology - Category: Microbiology Authors: Tags: J Med Microbiol Source Type: research
The objective of this study was to evaluate a novel automated random-access test, mariPOC CDI (ArcDia Ltd., Finland), for the detection of Clostridioides difficile glutamate dehydrogenase (GDH) and toxins A and B directly from fecal specimens. The mariPOC test was compared with both the GenomEra C. difficile PCR assay (Abacus Diagnostica Oy, Finland) and the TechLab C. diff Quik Chek Complete (Alere Inc.; now Abbot) membrane enzyme immunoassay (MEIA). Culture and the Xpert C. difficile assay (Cepheid Inc., USA) were used to resolve discrepant results. In total, 337 specimens were tested with the mariPOC CDI test and GenomE...
Source: Journal of Clinical Microbiology - Category: Microbiology Authors: Tags: Immunoassays Source Type: research
More News: Biochemistry | Clostridium Difficile